England Bryant R, Sayles Harlan, Michaud Kaleb, Caplan Liron, Davis Lisa A, Cannon Grant W, Sauer Brian C, Solow Elizabeth B, Reimold Andreas M, Kerr Gail S, Schwab Pascale, Baker Josh F, Mikuls Ted R
Veterans Affairs Nebraska-Western Iowa Health Care System, and University of Nebraska Medical Center, Omaha.
Veterans Affairs Nebraska-Western Iowa Health Care System, University of Nebraska Medical Center, Omaha, and National Data Bank for Rheumatic Diseases, Wichita, Kansas.
Arthritis Care Res (Hoboken). 2016 Jan;68(1):36-45. doi: 10.1002/acr.22642.
There has been limited investigation into cause-specific mortality and the associated risk factors in men with rheumatoid arthritis (RA). We investigated all-cause and cause-specific mortality in men with RA, examining determinants of survival.
Men from a longitudinal RA registry were followed from enrollment until death or through 2013. Vital status and cause of death were determined using the National Death Index. Crude mortality rates and standardized mortality ratios (SMRs) were calculated for all-cause, cardiovascular disease (CVD), cancer, and respiratory mortality. Associations with all-cause and cause-specific mortality were examined using multivariable Cox proportional hazards and competing-risks regression.
There were 1,652 men with RA and 332 deaths. The leading causes of death were CVD (31.6%; SMR 1.77 [95% confidence interval (95% CI) 1.46-2.14]), cancer (22.9%; SMR 1.50 [95% CI 1.20-1.89]), and respiratory disease (15.1%; SMR 2.90 [95% CI 2.20-3.83]). Factors associated with all-cause mortality included older age, white race, smoking, low body weight, comorbidity, disease activity, and prednisone use. Rheumatoid factor concentration and nodules were associated with CVD mortality. There were no associations of methotrexate or biologic agent use with all-cause or cause-specific mortality.
Men in this RA cohort experienced increased all-cause and cause-specific mortality, with a 3-fold risk of respiratory-related deaths compared to age-matched men in the general population. Further studies are needed in order to examine whether interventions targeting potentially modifiable correlates of mortality might lead to improved long-term survival in men with RA.
针对类风湿关节炎(RA)男性患者特定病因死亡率及其相关危险因素的研究有限。我们调查了RA男性患者的全因死亡率和特定病因死亡率,并研究了生存的决定因素。
对一个纵向RA登记处的男性患者从入组开始随访直至死亡或到2013年。使用国家死亡指数确定生命状态和死亡原因。计算全因、心血管疾病(CVD)、癌症和呼吸系统疾病死亡率的粗死亡率和标准化死亡率(SMR)。使用多变量Cox比例风险模型和竞争风险回归分析与全因死亡率和特定病因死亡率的相关性。
共有1652名RA男性患者,其中332人死亡。主要死亡原因是CVD(31.6%;SMR 1.77 [95%置信区间(95%CI)1.46 - 2.14])、癌症(22.9%;SMR 1.50 [95%CI 1.20 - 1.89])和呼吸系统疾病(15.1%;SMR 2.90 [95%CI 2.20 - 3.83])。与全因死亡率相关的因素包括年龄较大、白人种族、吸烟、体重低、合并症、疾病活动度和使用泼尼松。类风湿因子浓度和结节与CVD死亡率相关。使用甲氨蝶呤或生物制剂与全因死亡率或特定病因死亡率无关。
该RA队列中的男性患者全因死亡率和特定病因死亡率均有所增加,与一般人群中年龄匹配的男性相比,呼吸系统相关死亡风险高出3倍。需要进一步研究以检验针对可能可改变的死亡率相关因素的干预措施是否能改善RA男性患者的长期生存情况。